PIK3CB and female reproductive organ cancer: However, early clinical trials using PI3K pathway inhibitor monotherapy such as buparlisib in heavily pretreated gynecological cancers have shown limited efficacy, with overall response rates (ORR) generally below 10% [4], except for a few phase II trials demonstrating moderate efficacy (ORR 10–26%) in recurrent or persistent EC [15,16].